- Home
- OABI vs GPAT Comparison
OABI vs GPAT Comparison
Compare OABI & GPAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- GPAT
- Stock Information
- Founded
- OABI 2012
- GPAT 2020
- Country
- OABI United States
- GPAT United States
- Employees
- OABI N/A
- GPAT N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- GPAT
- Sector
- OABI Health Care
- GPAT
- Exchange
- OABI Nasdaq
- GPAT NYSE
- Market Cap
- OABI 389.7M
- GPAT 365.5M
- IPO Year
- OABI N/A
- GPAT 2024
- Fundamental
- Price
- OABI $3.65
- GPAT $10.29
- Analyst Decision
- OABI Strong Buy
- GPAT
- Analyst Count
- OABI 4
- GPAT 0
- Target Price
- OABI $9.00
- GPAT N/A
- AVG Volume (30 Days)
- OABI 569.4K
- GPAT 6.2K
- Earning Date
- OABI 03-19-2025
- GPAT 01-01-0001
- Dividend Yield
- OABI N/A
- GPAT N/A
- EPS Growth
- OABI N/A
- GPAT N/A
- EPS
- OABI N/A
- GPAT 0.30
- Revenue
- OABI $20,409,000.00
- GPAT N/A
- Revenue This Year
- OABI N/A
- GPAT N/A
- Revenue Next Year
- OABI $78.61
- GPAT N/A
- P/E Ratio
- OABI N/A
- GPAT $34.03
- Revenue Growth
- OABI N/A
- GPAT N/A
- 52 Week Low
- OABI $3.10
- GPAT $9.98
- 52 Week High
- OABI $6.55
- GPAT $10.30
- Technical
- Relative Strength Index (RSI)
- OABI 53.96
- GPAT N/A
- Support Level
- OABI $3.61
- GPAT N/A
- Resistance Level
- OABI $4.02
- GPAT N/A
- Average True Range (ATR)
- OABI 0.18
- GPAT 0.00
- MACD
- OABI 0.04
- GPAT 0.00
- Stochastic Oscillator
- OABI 58.89
- GPAT 0.00
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.